Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Transplantation. 2016 Dec;100(12):2630–2639. doi: 10.1097/TP.0000000000001465

Figure 5. CD28 blockade with FR104 inhibits T cell expansion and effectively suppresses xeno-GVHD.

Figure 5

Figure 5

NOD/Scid/γc−/− mice receiving NHP PBMNC (30×106 cells) were treated with control IgG Fab’ antibody or anti–CD28 mAb (FR104) to assess potency for preventing xenogeneic GVHD. (A) Schematic showing the antibody dosing schedule: 100 μg per injection; injections starting on day 0, and 3 times weekly for 4 weeks. (B) Kaplan-Meier survival curves for mice receiving PBMNC + control IgG (dashed line) or + anti–CD28 mAb (solid line) (p<0.001). (C) Average weight (percentage of initial) for mice surviving on a given day for different groups of mice. *P < 0.05 for anti–CD28 treated mice from days 17 to 21. (D) Average GVHD score for mice surviving on a given day for different groups of mice. *P < 0.05 for anti–CD28 treated mice on days 19 and 21. GVHD severity was measured by enumerating CD4+, CD8+ and CD4+8+ T cell numbers in circulation on day 18 (E) and at the end of the experiment (d100) (F). n=6 mice per group.